135 related articles for article (PubMed ID: 25435209)
1. Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies.
Crunkhorn S
Nat Rev Drug Discov; 2014 Dec; 13(12):879. PubMed ID: 25435209
[No Abstract] [Full Text] [Related]
2. IDO inhibitors move center stage in immuno-oncology.
Sheridan C
Nat Biotechnol; 2015 Apr; 33(4):321-2. PubMed ID: 25850038
[No Abstract] [Full Text] [Related]
3. Next-generation monoclonals less profitable than trailblazers?
Mitchell P
Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
[No Abstract] [Full Text] [Related]
4. Deal watch: BMS bets on biologic immunotherapies.
Nat Rev Drug Discov; 2009 Sep; 8(9):688-9. PubMed ID: 19721438
[No Abstract] [Full Text] [Related]
5. Market watch: upcoming market catalysts in Q3 2012.
Jeng R
Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
[No Abstract] [Full Text] [Related]
6. Project data sphere to make cancer clinical trial data publicly available.
Hede K
J Natl Cancer Inst; 2013 Aug; 105(16):1159-60. PubMed ID: 23904505
[No Abstract] [Full Text] [Related]
7. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
[No Abstract] [Full Text] [Related]
8. BIO 2006 Annual International Convention. Innovations in biotech in China and Italy.
Tear S; Zarkowska T
IDrugs; 2006 Jun; 9(6):386-9. PubMed ID: 16752303
[No Abstract] [Full Text] [Related]
9. Industry shifts focus to immunology and cancer.
Ledford H
Nature; 2008 Nov; 456(7218):6. PubMed ID: 19004069
[No Abstract] [Full Text] [Related]
10. Optimism after much pessimism: what next?
Milstein C; Waldmann H
Curr Opin Immunol; 1999 Oct; 11(5):589-91. PubMed ID: 10508713
[No Abstract] [Full Text] [Related]
11. Trial watch: Trends in clinical trial design complexity.
Getz KA; Campo RA
Nat Rev Drug Discov; 2017 May; 16(5):307. PubMed ID: 28417986
[No Abstract] [Full Text] [Related]
12. Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.
Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878969
[No Abstract] [Full Text] [Related]
13. Deal watch: Epizyme-Celgene deal signals interest in new class of epigenetic drugs.
Flemming A
Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743968
[No Abstract] [Full Text] [Related]
14. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
15. Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy.
Cully M
Nat Rev Drug Discov; 2015 Jun; 14(6):374-5. PubMed ID: 26027531
[No Abstract] [Full Text] [Related]
16. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
17. Buy buy bispecific antibodies.
Holmes D
Nat Rev Drug Discov; 2011 Oct; 10(11):798-800. PubMed ID: 22037028
[No Abstract] [Full Text] [Related]
18. Outsourcing clinical trials.
Hanauer SB
Nat Rev Gastroenterol Hepatol; 2009 Apr; 6(4):191. PubMed ID: 19347005
[No Abstract] [Full Text] [Related]
19. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
20. Deal watch: Merck bets on purine receptor revival.
Cully M
Nat Rev Drug Discov; 2016 Aug; 15(8):525. PubMed ID: 27444222
[No Abstract] [Full Text] [Related]
[Next] [New Search]
